Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 18;13(10):e0206011.
doi: 10.1371/journal.pone.0206011. eCollection 2018.

Antiplatelet Agents Maintain Arteriovenous Fistula and Graft Function in Patients Receiving Hemodialysis: A Nationwide Case-Control Study

Free PMC article

Antiplatelet Agents Maintain Arteriovenous Fistula and Graft Function in Patients Receiving Hemodialysis: A Nationwide Case-Control Study

Yung-Ho Hsu et al. PLoS One. .
Free PMC article

Erratum in


Background: In this study, we evaluated the effects of various medications on the patency of vascular access (VA) for hemodialysis.

Methods: We analyzed data from the Longitudinal Health Insurance Database of Taiwan. We adopted a case-control study design within a cohort of patients who had received regular hemodialysis between 2002 and 2012; 34,354 patients with first VA failure were identified, and the duration from VA creation date to the first VA failure date was calculated. We then classified these patients into two groups, namely arteriovenous fistula (AVF, n = 25,933) and arteriovenous graft (AVG, n = 8,421). Each group was further divided into two subgroups, namely short-term (<1 year) and long-term (≥1 year) patency.

Results: The risk factors for early VA failure were age ≥65 years, diabetes mellitus, hyperlipidemia, cerebral vascular disease, congestive heart failure, peripheral artery disease, and sepsis. Male sex, hypertension, cancer, and peptic ulcer were associated with early AVF failure. Antiplatelet therapy increased the AVF and AVG patency times with adjusted odds ratios of 0.748 (95% confidence interval [CI]: 0.703-0.796, p < 0.0001) and 0.810 (95% CI: 0.728-0.901, p = 0.0001), respectively. A significant decrease in the VA failure risk was observed with an increase in the cumulative defined daily dose of antiplatelet agents.

Conclusion: This nationwide study demonstrated that some risk factors were associated with early VA failure and that the use of antiplatelet agents prevented the loss of VA patency in a dose-response manner. Thus, antiplatelet drugs should be routinely administered to high-risk patients receiving dialysis.

Conflict of interest statement

The authors have declared that no competing interests exist.


Fig 1
Fig 1. Flowchart of selection criteria and process of patients receiving hemodialysis and experienced vascular access (VA) dysfunction.
The time of occurrence of VA dysfunction was used to define two subgroups, namely short-term (S) (<1 year) and long-term (L) (≥1 year) VA dysfunction. AVF, arteriovenous fistula; AVG, arteriovenous graft; ESRD, end-stage renal disease.

Similar articles

See all similar articles

Cited by 4 articles


    1. Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, et al. Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association. 2004;19(1):108–20. Epub 2003/12/13. . - PubMed
    1. Santoro D, Benedetto F, Mondello P, Pipito N, Barilla D, Spinelli F, et al. Vascular access for hemodialysis: current perspectives. International journal of nephrology and renovascular disease. 2014;7:281–94. Epub 2014/07/22. 10.2147/IJNRD.S46643 . - DOI - PMC - PubMed
    1. Lok CE, Foley R. Vascular access morbidity and mortality: trends of the last decade. Clinical journal of the American Society of Nephrology: CJASN. 2013;8(7):1213–9. 10.2215/CJN.01690213 . - DOI - PubMed
    1. Righetti M, Ferrario G, Serbelloni P, Milani S, Tommasi A. Some old drugs improve late primary patency rate of native arteriovenous fistulas in hemodialysis patients. Annals of vascular surgery. 2009;23(4):491–7. Epub 2008/11/01. 10.1016/j.avsg.2008.08.033 . - DOI - PubMed
    1. Group VAW. III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J Kidney Dis. 2001;37(1 Suppl 1):S137–81. Epub 2001/03/07. . - PubMed

Publication types


Grant support

This work was supported by Taipei Medical University (105-6102-001-102). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.